Journal
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
Volume 10, Issue 3, Pages 340-348Publisher
BENTHAM SCIENCE PUBL
DOI: 10.2174/187152711794653742
Keywords
Autoimmune disease; glial activation; neuroinflammation; neurodegeneration; prolyl oligopeptidase
Categories
Funding
- European Commission [HEALTH-F2-2008-223077]
- Marie Curie Programme [PIEF-GA-2009-254127]
Ask authors/readers for more resources
Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available